These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 4540250)
1. (S)-norepinephrine in the tissues of mice and rats given racemic erythro-3,4-dihydroxyphenylserine (DOPS). Porter CC; Torchiana ML; Stone CA Life Sci I; 1972 Aug; 11(16):787-95. PubMed ID: 4540250 [No Abstract] [Full Text] [Related]
2. [Synthesis of norepinephrine from 3,4-dihydroxyphenylserine by L-aromatic amino acid decarboxylase of the rat brain and kidneys]. Fujiwara H; Inagaki C; Ikeda Y; Tanaka C Nihon Yakurigaku Zasshi; 1976 Oct; 72(7):891-8. PubMed ID: 14060 [TBL] [Abstract][Full Text] [Related]
3. Role of catechol structure in the inhibitory effects of D-isomers of amino acids on the decarboxylation of L-5-hydroxytryptophan. Shikimi T; Inagaki C; Takaori S Experientia; 1978 Sep; 34(9):1188-9. PubMed ID: 309827 [TBL] [Abstract][Full Text] [Related]
4. The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. Bartholini J; Constantinidis J; Puig M; Tissot R; Pletscher A J Pharmacol Exp Ther; 1975 May; 193(2):523-32. PubMed ID: 1142103 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of enzymic decarboxylation of L-threo-3,4-dihydroxyphenylserine using hog renal L-aromatic amino acid decarboxylase. Inagaki C; Tanaka C Biochem Pharmacol; 1978 Apr; 27(7):1081-6. PubMed ID: 26357 [No Abstract] [Full Text] [Related]
6. L-Dopa and imipramine: biochemical and behavioral interaction. Friedman E; Gershon S Eur J Pharmacol; 1972 May; 18(2):183-8. PubMed ID: 5037381 [No Abstract] [Full Text] [Related]
7. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat. Henning M; Rubenson A J Pharm Pharmacol; 1970 Aug; 22(8):553-60. PubMed ID: 4394527 [No Abstract] [Full Text] [Related]
8. Potentiation of effects of L-dopa on conditioned avoidance behavior by inhibition of extracerebral dopa decarboxylase. Seiden LS; Martin TW Physiol Behav; 1971 Apr; 6(4):453-8. PubMed ID: 5148757 [No Abstract] [Full Text] [Related]
9. Behavior and biochemical effects of preferentially protecting monoamines in the brain against the action of reserpine. Butcher LL; Rhodes DL; Yuwiler A Eur J Pharmacol; 1972 May; 18(2):204-12. PubMed ID: 4537669 [No Abstract] [Full Text] [Related]
11. Dopamine, noradrenaline and 5-hydroxy-trytamine in relation to motor activity, fighting and mounting behaviour. II. L-dopa and DL-threo-dihydroxyphenylserine in combination with Ro 4-4602 and parachlorophenylalanine. Benkert O; Renz A; Matussek N Neuropharmacology; 1973 Mar; 12(3):187-93. PubMed ID: 4266876 [No Abstract] [Full Text] [Related]
12. Brain DOPA-5-HTP decarboxylase activity after the chronic administration of L-dopa or 5-hydroxy-L-tryptophan in normal and lesioned cats. Roberge AG; Poirier LJ Brain Res; 1974 Aug; 76(3):401-12. PubMed ID: 4546739 [No Abstract] [Full Text] [Related]
13. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic L-amino acid decarboxylase-serotonin-dopamine-norepinephrine). Christenson JG; Dairman W; Udenfriend S Proc Natl Acad Sci U S A; 1972 Feb; 69(2):343-7. PubMed ID: 4536745 [TBL] [Abstract][Full Text] [Related]
14. Enzymatic decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat heart. Ohmura I; Inagaki C; Araki H; Tanaka C Jpn J Pharmacol; 1978 Oct; 28(5):747-53. PubMed ID: 31501 [TBL] [Abstract][Full Text] [Related]
15. Interaction of DOPA decarboxylase inhibitors with the effect of alpha-methyldopa on blood pressure and tissue monoamines in rats. Henning M Acta Pharmacol Toxicol (Copenh); 1969; 27(2):135-48. PubMed ID: 5819569 [No Abstract] [Full Text] [Related]
16. Dopamine, noradrenaline and 5-hydroxy-tryptamine in relation to motor activity, fighting and mounting behavior. I. L-dopa and DL-threo-dihydroxyphenylserine in combination with Ro 4-4602, pargyline and reserpine. Benkert O; Gluba H; Matussek N Neuropharmacology; 1973 Mar; 12(3):177-86. PubMed ID: 4735415 [No Abstract] [Full Text] [Related]
17. Homologs of dopa, alpha-methyldopa, and dopamine as potential cardiovascular drugs. Winn M; Rasmussen R; Minard F; Kyncl J; Plotnikoff N J Med Chem; 1975 Apr; 18(4):434-7. PubMed ID: 1079053 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242 [TBL] [Abstract][Full Text] [Related]
19. Saligenin analogs of l-DOPA and dl-alpha-methyl-DOPA. Atkinson M; Hartley D; Lunts LH; Ritchie AC J Med Chem; 1974 Feb; 17(2):248-9. PubMed ID: 4809259 [No Abstract] [Full Text] [Related]
20. Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa. Kato T; Karai N; Katsuyama M; Nakamura M; Katsube J Biochem Pharmacol; 1987 Sep; 36(18):3051-7. PubMed ID: 3115271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]